Profile data is unavailable for this security.
About the company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
- Revenue in USD (TTM)0.00
- Net income in USD-16.87m
- Incorporated2013
- Employees3.00
- LocationMatinas BioPharma Holdings IncSuite 302, 1545 Route 206 SouthBEDMINSTER 07921United StatesUSA
- Phone+1 (908) 443-1860
- Fax+1 (302) 636-5454
- Websitehttps://www.matinasbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProtoKinetix, Inc. | 0.00 | -376.18k | 3.21m | 0.00 | -- | 12.77 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.34m | 4.00 | -- | 0.1914 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Vaccinex Inc | 601.00k | -18.63m | 3.35m | 23.00 | -- | -- | -- | 5.57 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 3.55m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.57m | 21.00 | -- | -- | -- | 31.87 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.78m | 3.00 | -- | 0.539 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Nymox Pharmaceutical Corp | -100.00bn | -100.00bn | 3.80m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0717 | -- | -- | -- | -- | -- | -397.74 | -- | -- | -- | -- | -- | -883,740.00 | -- | -- | -- | -- | -- | -- | 49.21 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 3.83m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -14.08m | 3.86m | 8.00 | -- | 0.1198 | -- | -- | -120.02 | -120.02 | 0.00 | 12.27 | 0.00 | -- | -- | 0.00 | -82.96 | -- | -118.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12,406.06 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 3.88m | -- | -- | 0.6078 | -- | 53.74 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Clearside Biomedical Inc | 3.33m | -26.00m | 3.92m | 32.00 | -- | -- | -- | 1.18 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Indaptus Therapeutics Inc | 0.00 | -16.87m | 3.95m | 7.00 | -- | 0.6274 | -- | -- | -31.67 | -31.67 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -223.71 | -56.08 | -317.86 | -68.84 | -- | -- | -- | -- | -- | -13.74 | 0.00 | -- | -- | -- | 2.60 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.03m | 3.00 | -- | 0.1757 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -8.01m | 4.09m | 21.00 | -- | 16.12 | -- | -- | -13.35 | -13.35 | 0.00 | 0.2178 | 0.00 | -- | -- | 0.00 | -154.83 | -132.71 | -183.46 | -155.93 | -- | -- | -- | -- | 1.31 | -- | 0.00 | -- | -- | -- | -14.39 | -- | -18.17 | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.26m | 8.00 | -- | 0.3339 | -- | 8.73 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
Data as of Feb 13 2026. Currency figures normalised to Matinas BioPharma Holdings Inc's reporting currency: US Dollar USD
5.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2025 | 55.97k | 0.87% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 49.65k | 0.78% |
| DRW Securities LLCas of 31 Dec 2025 | 46.37k | 0.72% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 40.11k | 0.63% |
| Holos Integrated Wealth LLCas of 31 Dec 2025 | 32.48k | 0.51% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 28.97k | 0.45% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 22.59k | 0.35% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 18.28k | 0.29% |
| Jane Street Capital LLCas of 31 Dec 2025 | 15.90k | 0.25% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 15.32k | 0.24% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
